An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

Opens in a new tab or window SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral therapy (ART) avoided rebound for 5 ...

The trial focused on broadly neutralizing antibodies (bNAbs), long-acting therapies designed to target and control the virus. Involving 68 participants living with HIV who stopped their daily ...

A query and indexing engine for Redis, providing secondary indexing, full-text search, vector similarity search and aggregations.

长效广谱中和抗体（LS-bNAbs）在停止ART后维持病毒控制的效果尚不明确。RIO研究旨在评估LS-bNAbs对比安慰剂对早期治疗HIV感染者的病毒控制频率和持久 ...

Broadly neutralising antibodies (bnAbs) have the potential to fill that gap. People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden ...

The RIO trial assessed the impact of two long-acting immune therapies known as broadly neutralising antibodies, or bNAbs, compared with placebo, among 68 people living with HIV who stopped taking ...

Professor John Frater from the University of Oxford, co-lead investigator, explained: “These bNAbs function in two ways—first, by directly targeting and killing HIV, and second, by stimulating new and ...

As a result, a consensus has emerged among researchers that to be effective, an HIV vaccine must be able to induce broadly neutralising antibodies (bNAbs). The "broadly" refers to the ability of these ...